During the development of novel hormonal therapies for prostate cancer, first in the castration-resistant metastatic setting and then in the castration-sensitive metastatic setting and even in the non-metastatic castration-resistant setting, the preservation of quality of life, treatment-related cognitive symptoms, and fatigue were factors used to differentiate the tolerance of abiraterone acetate and other next-generation androgen receptor inhibitors (such as enzalutamide, apalutamide, and darolutamide; see Table 3). Here, AR is linked to prostate carcinoma.